Lindsey M. Lyle, MS, PA-C, on AML: Results From an Early Phase Dose-Escalation and Dose-Expansion Trial

Lindsey M. Lyle, MS, PA-C, of the University of Colorado Cancer Center, discusses study findings on venetoclax in combination with hypomethylating agents, which induced rapid, deep, and durable responses in patients with acute myeloid leukemia who are ineligible for intensive therapy (Abstract 285).